At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 11 enrolled
Drug / intervention
DT388IL3drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Therapy Targeting the Interleukin-3 Receptor (IL3R) for Patients With Relapsed or Refractory and Elderly or Poor-Risk Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome With DTIL3 (IND# 11314): a Phase I/II Clinical Trial
University of Texas Southwestern Medical Center·interventional·Posted Nov 9, 2006·Updated Apr 23, 2019
In Brief
A Phase 2 clinical trial evaluating DT388IL3 for Leukemia and 2 related conditions. Completed, enrolled 11 participants across 1 site.
Detailed Summary
RATIONALE: Combinations of biological substances in DT388IL3 fusion protein may be able to carry cancer killing substances directly to the cancer cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of DT388IL3 fusion protein and to see how well it works in treating patients with acute myeloid leukemia or myelodysplastic syndromes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 2006
Enrollment StartMay 2013
Primary CompletionJul 2017
TodayJul 2026
First PostedNov 9, 2006
Enrollment StartMay 1, 2013
Primary CompletionJul 27, 2017
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 19.6 years ago
Interventions
DT388IL3drug
Intravenously via a 3 cc plastic syringe as a 15 minute bolus infusion daily for five days.